Catalent

global GMP capacity (Lonza Visp/US, Catalent, Thermo Fisher Patheon) that lets a sponsor manufacture in-region without owning a plant.

Country
United States
Commercial Global CDMO
Coverage
CNEUINUS
market-access-commercial
therapeutics-platforms
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Funding$1.15 billion in total fundingintuitionlabs.ai
CapacitySingle-use bioreactors up to 2,000 L; 16 GMP suites at Harmans/BWI; Madison site has multiple 2,000 L reactorsintuitionlabs.ai · catalent.com
CertificationFDA CGMP, EMA, PMDA, ANVISA, Russian Ministry of Health, ISO 14001, ISO 45001, Ecovadis GOLD, HPRA GMP certifiedcatalent.com
Regulatory approvalSupported multiple regulatory approvals including FDA CBER, EMA, PMDA, ANVISA, and Russian Ministry of Healthcatalent.com
Production siteMore than 40 global sites, including major hubs in Madison, WI and Harmans/BWI, MDcatalent.com
Revenue$4.38 billion (FY2024)intuitionlabs.ai · sec.gov

Independent sources: intuitionlabs.ai · sec.gov

Technologies
NameClusterRisk
Bioproduction CDMO/CMO (biologics/ATMP/mRNA)therapeutics-platformsLow
Local manufacturing for market accessmarket-access-commercialLow

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.